Investment Thesis
Cullinan Therapeutics is a pre-revenue biopharmaceutical company burning $46.1M annually in free cash flow with only $75.1M in cash on hand, implying ~1.6 years of runway at current burn rates. Zero revenue combined with significant operating losses (-$53.7M) and negative EPS (-$2.30) indicates the company has no commercial traction and faces a critical path dependency on securing additional funding or achieving major clinical/regulatory milestones to justify continued operations.
Strengths
- Strong balance sheet with $75.1M cash and minimal liabilities ($36.8M)
- Excellent liquidity position with 10.28x current ratio and zero long-term debt
- Positive stockholders' equity of $366.2M provides cushion for near-term operations
Risks
- Zero revenue indicates pre-commercial status or failed commercialization
- Annual cash burn of $46.1M reduces runway to approximately 1.6 years at current rate
- Significant operating losses (-$53.7M) and negative net income (-$49.7M) with no path to profitability visible
- Dilution risk from future financing needs to extend cash runway beyond current position
- No revenue generation or positive cash flow metrics visible in financial data
Key Metrics to Watch
- Quarterly cash burn trend and runway extension
- Clinical trial progress and regulatory milestones for pipeline programs
- Revenue generation timing and initial commercialization metrics
- Capital raise announcements and financing dilution impact
Financial Metrics
Revenue
0.0
Net Income
-49.7M
EPS (Diluted)
$-2.30
Free Cash Flow
-46.1M
Total Assets
403.0M
Cash
75.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-13.6%
ROA
-12.3%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
10.28x
Quick Ratio
10.28x
Debt/Equity
0.00x
Debt/Assets
9.1%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T08:48:14.983028 |
Data as of: 2026-03-31 |
Powered by Claude AI